AlivaMab Biologics
AlivaMab Biologics offers high-quality human antibody drug discovery and engineering with no license, milestone, or royalty fees. Using our advanced AlivaMab® Mouse-NGX and Mouse-SDX platforms, we enable rapid discovery of diverse antibody formats—including monoclonal IgG, human Single-Domain VH, bispecifics, ADCs, CARs, and more—tailored to complex targets like GPCRs and membrane multi-spanners. Our streamlined process delivers validated antibody sequences in just 3–4 months. To date, over 24 AlivaMab antibodies have entered clinical trials.
